Trivarx Ltd
TRI.ASXHealth Care
Development of diagnostic heart rate variability technology for mental health diagnosis
Market Data
$0.026
+0.0%$28.8M
-100000.0x
$-0.003
0.00%
+0.2%
Latest Earnings
Appendix 4D & Half-Year Financial Report to 31 December 2025
24 February 2026
TrivarX Limited reported a significant net loss of $1.26M for HY26 compared to $91K in the prior period, driven primarily by $7.97M in share-based payments related to strategic acquisitions. The company successfully completed a VA clinical trial demonstrating 88% sensitivity for depression screening and acquired the Stabl-Im brain imaging technology, while raising $4.2M to fund development activities. Key points: Completed successful VA clinical trial showing 88% sensitivity and 68% specificity for depression screening in veterans; Successfully acquired Stabl-Im brain imaging technology for potential early cancer detection using MRI; Raised $4.2M through strategic placement with strong institutional support including new investor Dr Daniel Tillett
Recent Announcements
Appendix 4D & Half-Year Financial Report to 31 December 2025
TrivarX Limited reported a significant net loss of $1.26M for HY26 compared to $91K in the prior period, driven primarily by $7.97M in share-based payments related to strategic acquisitions. The company successfully completed a VA clinical trial demonstrating 88% sensitivity for depression screening and acquired the Stabl-Im brain imaging technology, while raising $4.2M to fund development activities. Key points: Completed successful VA clinical trial showing 88% sensitivity and 68% specificity for depression screening in veterans; Successfully acquired Stabl-Im brain imaging technology for potential early cancer detection using MRI; Raised $4.2M through strategic placement with strong institutional support including new investor Dr Daniel Tillett
Get real-time alerts for TRI
Receive AI-powered earnings summaries and instant notifications when Trivarx Ltd releases results.
Register Free